IQVIA (NYSE:IQV) Insider Eric Sherbet Sells 4,446 Shares of Stock

IQVIA Holdings Inc. (NYSE:IQV – Get Free Report) insider Eric Sherbet sold 4,446 shares of IQVIA stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $278.83, for a total value of $1,239,678.18. Following the completion of the sale, the insider directly owned 24,989 shares in the company, valued at approximately $6,967,682.87. The trade was a 15.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

IQVIA Stock Down 1.2%

Shares of IQV opened at $271.11 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83. The stock has a market capitalization of $44.68 billion, a price-to-earnings ratio of 32.94, a price-to-earnings-growth ratio of 2.44 and a beta of 1.16. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $284.50. The business’s 50 day simple moving average is $267.67 and its 200-day simple moving average is $211.75.

IQVIA (NYSE:IQV – Get Free Report) last posted its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The firm had revenue of $4.43 billion during the quarter, compared to analyst estimates of $4.37 billion. During the same period last year, the firm posted $3.00 earnings per share. IQVIA’s revenue for the quarter was up 8.0% compared to the same quarter last year. As a group, equities analysts expect that IQVIA Holdings Inc. will post 11.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IQV. BlackRock Inc. bought a new position in IQVIA during the 2nd quarter valued at about $2,811,292,000. Dimensional Fund Advisors LP increased its holdings in IQVIA by 4.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock worth $282,657,000 after purchasing an additional 66,643 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of IQVIA by 9.0% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock valued at $315,772,000 after acquiring an additional 134,997 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of IQVIA in the second quarter valued at about $240,911,000. Finally, Bank of America Corp DE purchased a new stake in IQVIA in the second quarter worth about $235,551,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on IQV. Barclays boosted their target price on shares of IQVIA from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. HSBC increased their price target on shares of IQVIA from $280.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, September 1st. UBS Group initiated coverage on IQVIA in a research report on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price target for the company. Truist Financial lifted their price target on IQVIA from $329.00 to $346.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Finally, Mizuho boosted their price objective on IQVIA from $275.00 to $300.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $294.21.

Get Our Latest Report on IQVIA

IQVIA Company Profile

(Get Free Report)

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.

Featured Articles

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.